Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART

Eurosurveillance

Volumn 22, Issue 18, 2017, Pages

  Gubareva, L V ^a   Fallows, E ^b   Mishin, V P ^a   Hodges, E ^a   Brooks, A ^c,d   Barnes, J ^a   Fry, A M ^a   Kramp, W ^e   Shively, R ^e   Wentworth, D E ^a   Weidemaier, K ^b   Jacobson, R ^b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b BD Technologies   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^e Biomedical Advanced Research and Development Authority   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR; ANTIVIRUS AGENT; SIALIDASE;

ANTIVIRAL RESISTANCE; ARTICLE; BIOLUMINESCENCE; DRUG SURVEILLANCE PROGRAM; ENZYME ACTIVITY; GENE MUTATION; GOLD STANDARD; HUMAN; IC50; INFLUENZA A VIRUS (H1N1); INFLUENZA VIRUS; NONHUMAN; R FACTOR; SEQUENCE ANALYSIS; VIRAL GENETICS; VIRAL PHENOMENA AND FUNCTIONS; VIRUS LOAD; VIRUS PARTICLE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; INFLUENZA; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE; OSELTAMIVIR;

EID: 85019100595     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2017.22.18.30529     Document Type: Article

References (16)

1. Oh DY, Hurt AC. A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade. Scientifica (Cairo). 2014; 2014: 430629. doi: 10.1155/2014/430629 PMID: 24800107
2. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013; 98 (2): 174-85. doi: 10.1016/j.antiviral.2013.03.014 PMID: 23523943
3. Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, et al. Characterization of a large cluster of influenza A (H1N1) pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan. Antimicrob Agents Chemother. 2015; 59 (5): 2607-17. doi: 10.1128/AAC.04836-14 PMID: 25691635
4. Okomo-Adhiambo M, Fry AM, Su S, Nguyen HT, Elal AA, Negron E, et al., 2013–14 US Influenza Antiviral Working Group. Oseltamivir-resistant influenza A (H1N1) pdm09 viruses, United States, 2013-14.Emerg Infect Dis. 2015; 21 (1): 136-41. doi: 10.3201/eid2101.141006 PMID: 25532050
5. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A (H1N1) pdm09 influenza in Australia. J Infect Dis. 2012; 206 (2): 148-57. doi: 10.1093/infdis/ jis337 PMID: 22561367
6. Matsuzaki Y, Mizuta K, Aoki Y, Suto A, Abiko C, Sanjoh K, et al. A two-year survey of the oseltamivir-resistant influenza A (H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J. 2010; 7 (1): 53. doi: 10.1186/1743-422X-7-53 PMID: 20202225
7. Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis. 2009; 49 (12): 1828-35. doi: 10.1086/648424 PMID: 19911968
8. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012; 17 (1 Pt B): 159-73. doi: 10.3851/ IMP2067 PMID: 22311680
9. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012; 87 (39): 369-74.PMID: 23061103
10. Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R, Fry A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Res. 2014; 110: 31-41. doi: 10.1016/j. antiviral.2014.07.001 PMID: 25043638
11. Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelode-Andrade H, Besselaar T, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res. 2015; 117: 27-38. doi: 10.1016/j.antiviral.2015.02.003 PMID: 25721488
12. Thompson CI, Lackenby A, Daniels RS, McCauley JW, Pereyaslov D, Broberg EK, et al. Evaluation of influenza virus antiviral susceptibility testing in Europe: results from the first external quality assessment exercise. J Clin Virol. 2013; 56 (3): 212-8. doi: 10.1016/j.jcv.2012.11.005 PMID: 23201459
13. Okomo-Adhiambo M, Mishin VP, Sleeman K, Saguar E, Guevara H, Reisdorf E, et al. Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance. Antiviral Res. 2016; 128: 28-35. doi: 10.1016/j. antiviral.2016.01.009 PMID: 26808479
14. Marjuki H, Mishin VP, Sleeman K, Okomo-Adhiambo M, Sheu TG, Guo L, et al. Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens. Antimicrob Agents Chemother. 2013; 57 (11): 5209-15. doi: 10.1128/AAC.01086-13 PMID: 23917311
15. Tamura D, DeBiasi RL, Okomo-Adhiambo M, Mishin VP, Campbell AP, Loechelt B, et al. Emergence of Multidrug-Resistant Influenza A (H1N1) pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir. J Infect Dis. 2015; 212 (8): 1209-13. doi: 10.1093/ infdis/jiv245 PMID: 25943200
16. Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. 2014; 14 (2): 109-18. doi: 10.1016/S1473-3099 (13) 70267-6 PMID: 24268590